Supplementation of enteral nutritional formulas and parenteral nutrition lipid emulsions with omega-3 fatty acids is a recent area of research in patients with critical illness. It is hypothesized that omega-3 fatty acids may help reduce inflammation in critically ill patients, particularly those with sepsis and acute lung injury. The objective of this article is to review the data on supplementing omega-3 fatty acids during critical illness; enteral and parenteral supplemental nutrition are reviewed separately. The results of the research available to date are contradictory for both enteral and parenteral omega-3 fatty acid administration. Supplementation with omega-3 fatty acids may influence the acute inflammatory response in critically ill patients, but more research is needed before definitive recommendations about the routine use of omega-3 fatty acids in caring for critically ill patients can be made.

© 2010 International Life Sciences Institute

INTRODUCTION

The systemic inflammatory response syndrome (SIRS) and sepsis are the leading causes of death in critically ill patients in Western countries.1 Acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS), are inflammatory syndromes of hypoxemic respiratory failure and diffuse pulmonary infiltrates that are commonly caused by sepsis.2,3 ALI is defined by the presence of acute hypoxemia (defined as a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of ≤300, or ≤200 for ARDS) and new bilateral infiltrates on a frontal chest radiograph that are not attributable to left atrial hypertension.4 ALI is characterized by alveolar epithelial and pulmonary capillary endothelial disruption, and its pathogenesis is believed to result from uncontrolled activation of the inflammatory cascade after pulmonary and systemic insults, including sepsis, pneumonia, trauma, aspiration, inhalation injury, pancreatitis, and massive blood transfusion.5,6 There are approximately 200,000 cases of ALI per year in the United States and nearly 40% of ALI patients die.5,7 Not only is sepsis the most common risk factor for ALI, accounting for nearly 80% of cases, but patients with sepsis as their ALI risk factor generally have worse outcomes than patients with other risk factors.5,7

One feature of uncontrolled activation of the inflammatory response involves excessive production of proinflammatory cytokines and lipid-derived inflammatory mediators termed eicosanoids.8 As such, an important and relatively new area of critical care research regards the biological and clinical effects of lipids, provided both enterally and parenterally, during critical illness. Due to their anti-inflammatory properties, omega-3 fatty acids (FA) have been a particular focus of this research.

Omega-3 FAs are essential for normal growth and development and are thought to play a fundamental role in the prevention and treatment of coronary artery disease, diabetes, hypertension, arthritis, cancer, and other inflammatory and autoimmune disorders.9 In the last decade, new research has explored whether omega-3 FAs can decrease the production of inflammatory cytokines and eicosanoids and may thus offer benefit to patients...
with critical illness. This review examines the clinical research that has been conducted in which omega-3 FAs have been administered enterally or parenterally; its scope is generally limited to critically ill patients with sepsis or ALI, who often experience a more amplified inflammatory response than post-surgical or trauma patients.

**BIOLOGICAL EFFECTS OF OMEGA-3 FATTY ACIDS**

Humans are unable to synthesize omega-3 FAs de novo; they are essential. Omega-3 FAs are long-chain polyunsaturated fatty acids (PUFA) of 18–22 carbons in length with the first double-bond positioned at the third carbon atom from the methyl end of the fatty acid. Alpha-linolenic acid (ALA;18:3n-3) is the parent 18-carbon FA. The human body can synthesize longer omega-3 FAs such as eicosapentaenoic acid (EPA;20:5n-3) and docosahexanoic acid (DHA;22:6n-3) from ALA as seen in Figure 1. Omega-3 FAs are found in vegetable oils such as flaxseed, canola, linseed, and soy oils, but fish oil is by far the richest source of EPA and DHA. Omega-6 FAs are also essential PUFAs, with the first double-bond located at the sixth carbon from the methyl end. Linoleic acid (LA;18:2, n-6) is the shortest chain omega-6 FA and it is converted to gamma-linolenic acid (GLA;18:3, n-6) and arachidonic acid (AA;20:4, n-6). These omega-6 FAs are found primarily in corn, safflower, and sunflower oils. The chemical structure of omega-3 and omega-6 FAs dictates production of eicosanoid metabolic products, specifically prostaglandins, thromboxanes, leukotrienes, lipoxins, and hydroxyl FAs, which are directly involved in inflammation.11

The inflammatory response to infection or injury is extremely complex and, although normal following such an insult, can occur on a massive and uncontrolled scale, leading to additional tissue damage and potential further worsening of illness. Such uncontrolled activation of the inflammatory response has been implicated in the pathogenesis of both sepsis and ALI and is characterized by high levels of cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6.5,12–16 Other inflammatory mediators that also characterize inflammation are derived from phospholipids composing the membranes of immune cells, including macrophages, monocytes, and neutrophils. Omega-3 FAs are believed to have four main anti-inflammatory mechanisms of action that may be beneficial during critical illness: 1) metabolism into bioactive eicosanoid inflammatory mediators, 2) alteration of membrane lipid rafts, 3) inhibition of nuclear receptor activation (specifically NF-κB) to modulate production of inflammatory mediators, and 4) metabolism into resolvins and protectins.17

---

**Figure 1** Omega-3 and omega-6 fatty acids pathways in humans.
The particular FA components of the cell membrane provide substrate for production of lipid inflammatory mediators such as eicosanoids. PUFAs that are incorporated into human cellular membranes include EPA, DHA, omega-6 FA arachidonic acid (AA), and omega-9 FA oleic acid. Leukocyte membrane phospholipids are normally composed of 30% PUFAs. With consumption of a typical Western diet, the majority of PUFAs are omega-6 FAs (primarily AA), while a small percentage are omega-3 FAs. When the inflammatory cascade is activated by a stimulus, a macrophage can mobilize 25% to 40% of its membrane lipid content to produce free AA. Free AA is then further metabolized by cyclooxygenase (COX) and 5-lipoxygenase (LOX) into pro-inflammatory eicosanoids, including the 2-series prostaglandins and thromboxanes and the 4-series leukotrienes (Figure 1). The role of the eicosanoids in inflammation is well known, especially prostaglandin E2 (PGE2), thromboxane A2 (TXA2), and leukotriene B4 (LTB4). PGE2 induces fever, vascular permeability, and vasodilation during sepsis. TXA2 promotes vascular permeability, platelet aggregation, leukocyte adhesion, and bronchoconstriction. TXA2 may also play a role in early sepsis and organ injury due to its pro-thrombotic effects leading to tissue ischemia. LTB4 activates leukocytes, resulting in generation of reactive oxygen species, release of proteases such as elastase, neutrophil chemotaxis, and synthesis of lipid mediators.

Omega-3 FAs can affect eicosanoid metabolism through a variety of mechanisms. Increased dietary consumption of EPA and DHA will result in increased incorporation into inflammatory cell membranes. Because omega-3 FAs replace AA in the phospholipid membrane, AA concentration is reduced, thus resulting in decreased production of the highly inflammatory AA-derived eicosanoids due to substrate restriction. In addition to replacing AA in immune cell membranes, EPA also 1) inhibits the metabolism of free AA into the inflammatory eicosanoids and 2) is metabolized itself to different eicosanoids (PGE2 and LTB4) that are considered less pro-inflammatory than those derived from AA. These mechanisms have been proven in animal studies where fish oil consumption has been shown to decrease the production of AA-derived eicosanoids by immune cells by 40–70%. Due to its structure, it has recently been suggested that DHA may substantially influence basic properties of cell membranes, including fluidity, compressibility, and permeability, and thus be able to alter lipid raft behavior and function. This, in turn, may significantly affect cellular signal transduction and inflammatory processes.

Another mechanism by which omega-3 FAs may ameliorate inflammation is via inhibition of nuclear factor kappa B (NF-κB). NF-κB is a key transcription factor involved in the upregulation of inflammatory cytokine and adhesion molecule production. It is activated by phosphorylation of an inhibitory subunit (I-κB) triggered by extracellular inflammatory stimuli. Several recent studies have suggested that EPA and DHA may directly affect inflammatory gene expression (and thus cytokine production) by inhibiting NF-κB activation, although the exact mechanism of inhibition remains unclear.

Finally, an additional anti-inflammatory mechanism of action involving EPA and DHA has recently been described. Over the past several years, it has been discovered that resolution of inflammation is an active process, rather than mere absence of inflammatory signals. Novel molecules called resolvins and protectins, lipid mediators derived from EPA and DHA with potent anti-inflammatory and neuroprotective properties, have been found to play an important role in the repair and resolution of inflammation. Resolvin (Rv) E1 and Protectin D1 are mediators that have been effective in resolving animal models of airway inflammation and colitis. RvE1 has also been found to inhibit NF-κB production by binding to an orphan receptor called ChemR23.

Although supplementation with omega-3 FAs is generally thought to reduce the unfavorable inflammatory effects of omega-6 FAs through the mechanisms described above, one omega-6 FA, gamma-linolenic acid (GLA), may also provide benefit in critical illness. GLA is found in evening primrose oil, black current seeds, and borage oil and is rapidly converted to dihomog-GLA, which is incorporated into immune cell phospholipids. Dihomo-GLA would then be expected to be preferentially converted to AA; however, it actually reduces the availability of AA and synthesis of AA-derived eicosanoids through mechanisms that are not yet clear. Dihomo-GLA is further metabolized to prostaglandin E1 (PGE1), a strong vasodilator of pulmonary and systemic circulation (Figure 1). GLA has been shown in animal models of critical illness to have an additive effect with EPA and DHA to decrease inflammation and organ failure.

With this potential additive effect in mind, much of the research investigating the effects of omega-3 FAs in
critically ill patients with sepsis and ALI has been conducted using a commercially available enteral feeding formula that contains EPA, DHA, GLA, and several antioxidant vitamins. This commercial feeding formula has been evaluated in several industry-sponsored animal studies. It has been shown to decrease AA concentration in inflammatory cell membranes; reduce alveolar concentrations of LTB4, PGE2, and TXB2; decrease pulmonary capillary permeability; and reduce alveolar neutrophil accumulation in endotoxemic rats.

**ENTERAL OMEGA-3 FATTY ACIDS IN ACUTE LUNG INJURY AND SEPSIS**

Three randomized clinical trials (RCTs) investigating a commercial feeding formula containing EPA, DHA, GLA, and antioxidants in critically ill patients have been completed and published (Table 1). Two of these RCTs studied patients with ALI and the third studied patients with sepsis (although nearly all of the patients in the third RCT had single-organ lung failure and thus had ALI). Two other similar but smaller studies have also been conducted, but they are either unpublished or only published in abstract form and will not be reviewed here.

All three of these trials randomized patients to receive either the enteral formula containing EPA, DHA, GLA, and antioxidants (Oxepa®; Abbott Nutrition, Abbott Laboratories, Columbus, Ohio, USA) or a control formula equal in fat, protein, and carbohydrate content but not containing fish oil. Both Oxepa® and the control formulas were considered high-fat (55% of calories), low-carbohydrate (28% of calories) enteral formulas as compared to standard polymeric enteral products that contain an average of 30% fat and 50% carbohydrate. Two different control formulas were used in the three RCTs, and they differed in lipid content. The lipid content of the control formula used by Gadek et al. and Singer et al. was 97% corn oil, which is high in linoleic acid, an omega-6 FA. The lipid in the control formula used by Pontes-Arrudas et al. was 55.8% canola oil, 14% corn oil, 20% medium-chain triglycerides, 7% high oleic safflower oil, and 3.2% soy lecithin.

In the first study, subjects in the investigational group received approximately 7 g EPA, 3 g DHA, and 6 g GLA per day. Serial bronchoalveolar lavage (BAL) was done at study entry, day 4, and day 7. Of the 146 patients enrolled, 48 were excluded from main analyses of biological outcomes, although intention-to-treat analyses were done on clinical outcomes. The treatment group had improved oxygenation at days 4 and 7 (P < 0.0499); reduced BAL fluid neutrophil (representing decreased lung inflammation) count at day 4 (P = 0.008); and decreased duration of mechanical ventilation (P = 0.027), ICU length of stay (P = 0.016), and new organ failures (P = 0.018). Mortality was 25% in the control group and 16% in the treatment group (P = 0.165).

In the second trial, patients in the EPA/DHA/GLA/antioxidant group had a shorter, but statistically insignificant, duration of mechanical ventilation. Oxygenation was improved at days 4 and 7 (P < 0.05) but not at day 14. Hospital length of stay was not different between the two groups. Mortality at 3 months after study enrollment was unexpectedly high at 75% in both groups.

The third trial in patients with sepsis, most of whom had ALI, found significant increases in ICU-free days (P < 0.001), ventilator-free days (P < 0.001), oxygenation status (P < 0.0001), and 28-day survival (52% versus 33%, P = 0.04) in the treatment group. Patients receiving the formula enriched with EPA, DHA, and GLA also had reduced development of new organ dys-

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Summary of enteral nutrition studies.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>ARDS, n = 146</td>
</tr>
<tr>
<td>Mean fatty acid intake</td>
<td></td>
</tr>
<tr>
<td>EPA (g/day)</td>
<td>6.9</td>
</tr>
<tr>
<td>DHA (g/day)</td>
<td>2.9</td>
</tr>
<tr>
<td>GLA (g/day)</td>
<td>5.8</td>
</tr>
<tr>
<td>Significant findings*</td>
<td></td>
</tr>
<tr>
<td>Improved oxygenation</td>
<td>Yes</td>
</tr>
<tr>
<td>Reduced ICU length of stay</td>
<td>Yes</td>
</tr>
<tr>
<td>Reduced ventilator time</td>
<td>Yes</td>
</tr>
<tr>
<td>Reduced 28-day mortality</td>
<td>No</td>
</tr>
<tr>
<td>Reduced new organ failure</td>
<td>Yes</td>
</tr>
</tbody>
</table>

* Statistically significant (P < 0.05).
† Days 4 and 7 only.
‡ Day 7 only.

**Abbreviations:** P, prospective; R, randomized; C, controlled; DB, double blind; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; GLA, gamma-linolenic acid; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; FA, fatty acid.
have suggested that formulas containing arginine may benefit elective surgical patients but may be harmful to critically ill patients with sepsis. Use of these formulas in critically ill patients showed a trend toward higher mortality where there was no such effect in elective surgical patients. Therefore, a negative effect or lack of benefit with use of these arginine-containing formulas in critically ill patients may be related to the arginine and not the omega-3 FAs, and these studies are therefore not included in this review.

When pharmaconutrients are added to enteral feedings and combined with macronutrients, it is difficult to generalize study results. Two recently completed, but not yet published, RCTs of omega-3 FAs in patients with ALI were designed to dissociate the pharmaconutrients from enteral feedings; the pharmaconutrients were administered as medications through enteral feeding tubes while patients received standard enteral nutrition regimens. The preliminary results of these two recent RCTs were presented orally at the American Thoracic Society (ATS) International Conference held May 15–20, 2009 in San Diego, California, and both of these trials appear to challenge the positive results found in the previous RCTs using the enteral formula containing EPA, DHA, GLA, and antioxidants. The OMEGA study was a large phase III RCT conducted by the National Institutes of Health, National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome Network (ARDSnet) to investigate an enteral supplement (delivered twice daily) containing EPA, DHA, GLA, and antioxidants in patients with ALI. This RCT was stopped in March 2009 after accrual of 272 of the planned 1,000 patients due to a lack of efficacy. The enteral supplement did not improve the outcomes of death at 60 days, ventilator-free days at day 28, or ICU-free days at day 28. A phase II randomized, double-blind, placebo-controlled trial of enteral fish oil (EPA and DHA) has also been conducted in 90 critically ill patients with ALI and the results are awaiting publication. In this RCT, fish oil or a saline placebo was given enterally as a medication, separate from enteral or parenteral nutrition. The primary endpoint was BAL fluid IL-8, and secondary endpoints included clinical outcomes as well as biomarkers of inflammation and injury, lung compliance, and oxygenation. None of the biologic or clinical endpoints were significantly different between the treatment and control groups. Based on the preliminary results available from these two RCTs, it is currently unclear if enteral omega-3 FAs are beneficial in patients with sepsis and ALI. Some limitations of the prior studies using the enteral formula enriched with EPA, DHA, GLA, and antioxidants include the small number of published studies to date, and the use in two of the studies of a control formula that was high in linoleic acid, an omega-6 FA. Further research will be needed.
before any definitive recommendations can be made about enteral omega-3 FA supplementation in critically ill patients.

**INCLUSION OF OMEGA-3 FATTY ACIDS IN PARENTERAL NUTRITION**

Lipid emulsions are generally administered in parenteral nutrition (PN) regimens in order to provide a source of calories and essential FAs, but the type of FAs included in the emulsions may have an impact on the inflammatory response in critical illness. The lipid traditionally used in parenteral nutrition regimens is soybean oil, in which approximately 54% of the FAs are the omega-6 FA linoleic acid. Concern has been expressed that a lipid emulsion high in linoleic acid might be pro-inflammatory, pro-coagulatory, immunosuppressive, and potentially harmful. However, clinical trials using these omega-6 FA-rich emulsions have provided conflicting evidence.

A meta-analysis of two studies in which total PN was administered in critically ill patients suggested that PN with standard lipids may result in a higher infectious complication rate ($P = 0.02$) than PN infused without lipids, although there was no difference in mortality rate. The suggestion that soybean oil-based lipid emulsions may not be ideal for critically ill patients has led to new formulations that replace some of the soybean oil with other oils such as medium-chain triglycerides, olive oil, or fish oil.

Recent studies have been conducted in critically ill patients using parenteral lipid formulations that contain EPA and DHA from fish oil. In a study by Mayer et al., 21 patients with sepsis and intolerance to enteral nutrition (i.e., requiring PN) were randomized in an open-label trial to receive an omega-3 FA-rich lipid emulsion (Omegaven®; Fresenius Kabi, Bad Homburg, Germany) or a standard omega-6-rich lipid emulsion (Lipoven®; Fresenius Kabi) for 5 days. Table 2 shows the FA composition of these two lipid emulsions. The administration of the omega-3-rich emulsion induced an increase in omega-3-free FAs in plasma and reversed the omega-3/omega-6 ratio, favoring EPA and DHA over AA, and reaching maximum effect in 3 days. Patients receiving the fish oil emulsion had rapid incorporation of EPA and DHA into leukocyte and monocyte cell membranes, increasing the concentration of each approximately threefold. Ex vivo, these cells produced approximately 30% less TNF-$\alpha$, interleukin 1-$\beta$, IL-6, and IL-8 when stimulated by endotoxin. However, there was no difference in serum cytokine levels between the patient groups receiving PN supplemented with omega-3 FAs and the standard lipid emulsion. In another smaller study by the same authors, 10 patients with septic shock and requiring parenteral nutrition were randomly assigned to receive either fish oil-fortified Omegaven* or the standard omega-6-rich Lipoven* (Table 2) for a total of 10 days. C-reactive protein concentrations and leukocyte counts decreased in those receiving the omega-3 emulsion and increased in the group receiving the omega-6 emulsion, although the differences were not statistically significant ($P = 0.08$ and $P = 0.09$, respectively). Patients infused with omega-6 lipids exhibited a trend towards longer ventilation time ($P = 0.07$). An increase in LTB$_5$ was seen only in the group receiving omega-3 lipids, approaching an LTB$_5$/LTB$_4$ ratio of almost 20% by the end of the study infusion period. Trends were also seen with increases in plasma omega-3-free FAs, the TXA$_3$/TXA$_2$ ratio, and platelet-activating factor synthesis in the group receiving the omega-3 rich lipid emulsion. Although these studies do not have the power to definitively state that infusion of omega-3 FA in patients with septic shock will modulate inflammatory mediator production and reduce inflammation, the results tend to support this hypothesis.

**Table 2** Fatty acid composition of omega-3- and omega-6-rich intravenous lipid emulsions.

<table>
<thead>
<tr>
<th>Fatty acid name</th>
<th>Shorthand nomenclature</th>
<th>Omega-3 lipid emulsion (Omegaven®)</th>
<th>Omega-6 lipid emulsion (Lipoven®)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myristic acid</td>
<td>C14:0</td>
<td>4.9</td>
<td>–</td>
</tr>
<tr>
<td>Palmitic acid</td>
<td>C16:0</td>
<td>10.7</td>
<td>12.4</td>
</tr>
<tr>
<td>Palmitoleic acid</td>
<td>C16:1n-7</td>
<td>8.2</td>
<td>–</td>
</tr>
<tr>
<td>Stearic acid</td>
<td>C18:0</td>
<td>2.4</td>
<td>5.0</td>
</tr>
<tr>
<td>Oleic acid</td>
<td>C18:1n-9</td>
<td>12.3</td>
<td>24.1</td>
</tr>
<tr>
<td>Linoleic acid (LA)</td>
<td>C18:2n-6</td>
<td>3.7</td>
<td>52.2</td>
</tr>
<tr>
<td>Alpha-linolenic acid (ALA)</td>
<td>C18:3n-3</td>
<td>1.3</td>
<td>8.2</td>
</tr>
<tr>
<td>Arachidonic acid (AA)</td>
<td>C20:4n-6</td>
<td>2.6</td>
<td>–</td>
</tr>
<tr>
<td>Eicosapentaenoic acid (EPA)</td>
<td>C20:5n-3</td>
<td>18.8</td>
<td>–</td>
</tr>
<tr>
<td>Docosapentaenoic acid</td>
<td>C22:5n-3</td>
<td>2.8</td>
<td>–</td>
</tr>
<tr>
<td>Docosahexaneoic acid (DHA)</td>
<td>C22:6n-3</td>
<td>16.5</td>
<td>–</td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td>16.1</td>
<td>–</td>
</tr>
</tbody>
</table>
Administration of an omega-3 FA-rich infusion (Omegaven®) during PN was reported in a prospective, open-label trial to improve diagnosis-related clinical outcomes in critically ill patients after major abdominal surgery \((n=255)\) or who were experiencing peritonitis and abdominal sepsis \((n=276)\), non-abdominal sepsis \((n=16)\), multi-trauma \((n=59)\), severe head injury \((n=18)\), or other diagnoses \((n=37)\).\(^7^9\) All patients received Omegaven®, which contains fish oil, in doses between 0.005 and 0.426 g/kg/day; the variation was because the dosage was at the discretion of the attending physician. A significant reduction in the length of both ICU stay and hospital stay \((P < 0.001)\) was found with doses of >0.05 g fish oil/kg/day. Mortality was also significantly reduced \((P < 0.05)\) in patients receiving >0.1 g fish oil/kg/day. A difference in mortality effect was observed for the different diagnosis groups with significant benefit seen in patients with severe head injury and multiple trauma \((P < 0.0001)\), followed by patients with abdominal sepsis \((P = 0.0027)\). A need for antibiotic treatment was higher in the patients receiving fish oil doses <0.15 g/kg/day. Although the study was not controlled or blinded, these results suggest clinical benefit from the inclusion of omega-3 FAs in PN regimens in these populations. The question of clinical benefit was further explored in a recent randomized, controlled trial using the PN lipid emulsions \((20\% \text{ Omegaven}^\circledast + 80\% \text{ Lipoven}^\circledast \text{ or Lipoven}^\circledast \text{ alone})\) in 40 patients with severe acute pancreatitis for 5 days.\(^7^8\) In this study, there were no significant differences between groups in white blood cell counts, rates of organ dysfunction, the number of infections, or the length of ICU stay. However, it is of interest that the plasma IL-6 level was reduced in the omega-3 FA group and slightly increased in the control group. Improvements were seen in both the C-reactive protein level and gas exchange by day 6 \((P < 0.05)\) and there was a reduced need for continuous renal replacement therapy \((P < 0.05)\) in the patients receiving fish oil.

In contrast to the generally positive results of the previous studies that were conducted primarily in critically ill surgical patients, a randomized, double-blind, controlled trial in critically ill medical patients did not find clear medical benefit to the provision of omega-3 FAs in parenteral lipid emulsions.\(^7^9\) A total of 166 medical ICU patients were randomized to receive a mixture of medium- and long-chain triglycerides (Lipofundin MCT®; Braun Medical, Melsungen, Germany) or a combination of Omegaven® and Lipofundin MCT® for 7 days. The primary endpoint was a more rapid reduction in plasma IL-6 and greater monocyte expression of HLR-DR (a marker of immune competence) in the group receiving omega-3 FAs. No differences were found between the groups in IL-6 or HLA-DR, nor were differences detected in mortality, duration of mechanical ventilation, length of ICU stay, number of infections, additional immune and inflammatory markers, or bleeding events. The authors speculated that one possible reason an effect was not seen in this study was that the intervention may have been initiated after the inflammatory process was fully activated in these severely ill patients; this is in comparison with the surgical patients in whom fish oil supplementation was most beneficial when administered before surgery.\(^6^0\) The study may also have been underpowered. In addition, this study used a control lipid emulsion that was lower in omega-6 FAs, due to the presence of medium-chain triglycerides, than the standard lipid emulsion; thus, the average daily dose of linoleic acid was reduced, which potentially resulted in an control formula that was less inflammatory.\(^7^9\)

No adverse effects have been reported with the administration of lipid emulsions fortified with fish oil, which suggests they are safe to use in critically ill patients.\(^7^1\) The prior trials of omega-3-rich parenteral lipid emulsions are summarized in Table 3. Because the research available to date provides conflicting data on the effect of omega-3 FA-fortified lipid emulsions in critically ill patients, its influence on inflammatory processes and clinical outcomes remains unclear.

**CONCLUSION**

The clinical use of omega-3 FAs in critically ill patients appears to be safe. However, based on the research that has been completed to date, it is not possible to definitively determine whether or not enteral or parenteral supplementation with omega-3 FAs has a positive effect on the inflammatory response, immune function, or clinical outcomes in critically ill patients with sepsis or ALI. Although research conducted on animals and on healthy subjects has provided a great deal of knowledge about the mechanism of action of omega-3 FAs and their effect on cytokines and inflammatory mediators, it remains unclear if the delivery of omega-3 FAs after the onset of severe stress is beneficial. Much of the available data is contradictory, or at least inconclusive, because studies conducted to date have been small and single-center, have lacked intention-to-treat analyses, have used a variety of enteral or parenteral formulas, and had heterogeneous patients.

Studies involving nutritional support and pharmaconutrient therapy in critically ill patients are particularly difficult to conduct and interpret for multiple reasons. First, most critical care research is difficult due to issues with surrogate consent and a short window of time for enrollment (e.g., most trials require enrollment within 24–48 h after ICU admission in order to initiate treatment early in the course of critical illness). Second,
critically ill patients are a very heterogeneous population and present with a variety of severe medical problems. Due to this heterogeneity, large numbers of patients are required to demonstrate an effect. Third, the delivery of enteral nutrition and pharmaconutrients is often interrupted or poorly tolerated in patients with severe illness. Fourth, complicating the analysis of an effect of omega-3 FAs is that FAs in many studies are often added to existing enteral nutrition formulas or lipid emulsions that contain macronutrients and other pharmaconutrients, thus making it difficult to interpret the results and discern which agent produced the effect. Fifth, in many trials the choice of control group agent is an issue, with patients often receiving higher than usual doses of omega-6 FAs. Sixth, when conducting large clinical trials, it is difficult to obtain many biological specimens at multiple clinical sites, thus making mechanistic studies more difficult. Finally, dosing data and pharmacokinetics studies of both enteral and parenteral omega-3 FAs in critically ill patients are virtually nonexistent.

All of the research showing a positive effect with enteral administration of omega-3 FAs in patients with sepsis and ALI involved the use of one enteral formula fortified with EPA, DHA, GLA, and antioxidants, as well as a high-fat control formula that is rarely used in routine clinical care. The studies of parenteral omega-3 FA supplementation that suggest a positive effect have been conducted using a particular fish oil lipid emulsion (Omegaven®) while controls have received a soybean oil-based emulsion high in potentially inflammatory omega-6 FAs. New research should focus on determining the pharmacokinetics and optimal dosing of omega-3 FA in critically ill patients. Additional randomized, double-blind, controlled clinical trials in which the omega-3 FAs are administered separately from standard enteral feeding formulas that are devoid of other pharmaconutrients, and in which the control agent is truly inert, are needed in order to definitively inform patient care.

**REFERENCES**


